Brickell Biotech is a clinical-stage pharmaceutical company that is working to develop innovative prescription therapeutics that can treat skin diseases. The company's focus is on debilitating skin conditions such as hyperhidrosis and other prevalent dermatological conditions. With its executive management team and board of directors bringing extensive experience in product development and global commercialization, Brickell aims to develop and commercialize innovative products that can be successful in the currently underserved dermatology global marketplace. The company's pipeline consists of potential novel therapeutics, and its strategy is to leverage its experience to in-license, acquire, develop, and commercialize innovative products.